



Date: 13 December 2019

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

UNLISTED OPTIONS EXPIRING 18 JANUARY 2020

Sydney, 13 December 2019: Noxopharm Limited (ASX: NOX) advises that the following options are due to expire as follows:

<u>Option Type</u>	<u>Number of options</u>	<u>Exercise Price</u>	<u>Expiry Date</u>
Unlisted	3,000,000	\$0.80	18 January 2020

Any participant wishing to exercise their options must forward a completed option exercise form and payment prior to 5.00pm (AEDT) prior to the expiry date.

.....

About Nyrada

Nyrada is a U.S. company registered as a foreign company in Australia. Nyrada started as a spin-off company of Noxopharm and is a pre-clinical stage, drug discovery and development company specializing in novel small molecule drugs pertaining to cardiovascular, neurological and chronic inflammatory diseases. The Company's two leading R&D programs are (i) an oral PCSK9-inhibitor (cholesterol-lowering drug), and (ii) a neuroprotectant to limit brain damage following stroke and traumatic brain injury.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company focusing on oncology drugs with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda[®] for the treatment of late-stage cancers including prostate cancer and sarcomas and is the major shareholder in Nyrada Inc.



Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: David.Franks@atomicgroup.com.au

U.S. Media Contact:

Frank de Maria
Purposeful Communications
T: +1 347 647 0284
E: frank.demaria@purposefulcommunications.com

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.